Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T22:21:20.659Z.
Calculation as of: 2026-10-06T22:21:20.659Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c88c4f39e0f2b8ce509c05ad310ef4a925915372bb385716b1b31bbca6f45484
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$30.19M
EV/FCF Ratio
21.82x
TTM Avg
18.76x
3Y Avg
19.10x
5Y Avg
19.10x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Context Therapeutics Inc. (CNTX) | $29.57M | N/A | N/A | N/A | N/A |
| GridAI Technologies Corp. (GRDX)vs › | $29.74M | N/A | N/A | N/A | N/A |
| Quantum Cyber N.V. (QUCY)vs › | $29.37M | N/A | N/A | N/A | N/A |
| MIRA Pharmaceuticals, Inc. (MIRA)vs › | $29.91M | N/A | N/A | N/A | N/A |
| Rockwell Medical, Inc. (RMTI)vs › | $30.19M | 21.82x | 18.76x | 19.10x | 19.10x |
| SCYNEXIS, Inc. (SCYX)vs › | $30.44M | N/A | 2.93x | 2.93x | 2.93x |
| BeyondSpring Inc. (BYSI)vs › | $28.47M | N/A | N/A | N/A | N/A |
| MDxHealth S.A. (MDXH)vs › | $30.81M | N/A | N/A | N/A | N/A |
| OneMedNet Corporation (ONMD)vs › | $28.31M | N/A | 3.61x | 3.61x | 3.61x |
| CervoMed Inc. (CRVO)vs › | $30.92M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute